To be fair to Lisa, she had not heard from Oncolix since initial trial had ended, which was back in 2016. I highly doubt she knew when I spoke to her that Oncolix had become a public entity. There is no law saying she cannot discuss information regarding a clinical trial of a private company. Oncolix was a private company at the time when the trial was taking place. She clearly fields calls all day long from people asking about the status of trials. When she initially picked up she was like "aren't you the one that just called me yesterday?". I'm certain that Lisa knows what she can and cannot do in regards to her job and what she is allowed to disclose.
She wasn't giving me any specific details. I asked her why the company had only 3 patients and she said there were a lot more, but they only had enough of the drug to complete 3. I asked if she knew why there was a shortage and she said it was most likely do to finances, but didn't know for sure, and that it happens to smaller biotech's quite often. I also asked her why they didn't post the results on the clinicaltrials.gov website and she replied that its up to the sponsor to update the trial pages and its likely due to the trial being incomplete. I told her about Oncolix claiming that there was evidence of efficacy and if she could elaborate on that. She didn't give any specific details, but said it was a shame that the trial had ended because the patients were improving. I asked her about the safety of Prolanta and she said that the drug was well tolerated by everyone they had tested on. Remember there was less than 18 people that it was tested on, the exact number I have no idea. But if it was big trial with 100's of patients, I am sure that not all of them would have tolerated the drug. It's just a really, really small sample size.
Obviously none of this means a whole lot until the trial is officially complete and we get the final results. But at the very least it is encouraging.
